128092-72-8

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzenemethanol, 2-fluoro-a-(4-fluorophenyl)-a-phenylis used as an intermediate in the synthesis of pharmaceuticals. Its unique structure and the presence of fluorine atoms make it a valuable building block for the development of potential drug candidates, particularly in the design of novel therapeutic agents.
Used in Agrochemical Synthesis:
In the agrochemical industry, Benzenemethanol, 2-fluoro-a-(4-fluorophenyl)-a-phenylis utilized as a key intermediate in the synthesis of various agrochemicals. Its specific properties, conferred by the fluorine atoms, can enhance the effectiveness and selectivity of these compounds in agricultural applications.
Used in Organic Synthesis:
Benzenemethanol, 2-fluoro-a-(4-fluorophenyl)-a-phenylserves as a versatile building block in organic synthesis. Its unique structure allows for further functionalization and modification, making it a valuable component in the synthesis of complex organic molecules and specialty chemicals.
Used in Industrial Applications:
The presence of fluorine atoms in the structure of Benzenemethanol, 2-fluoro-a-(4-fluorophenyl)-a-phenylmay impart specific properties that are desirable for various industrial applications. These properties can include enhanced stability, reactivity, or selectivity, making it a valuable component in the development of new materials and processes.

Upstream product

• 342-24-5 o-fluorobenzophenone 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 342-25-6 2,4'-difluorobenzophenone 
• 100-58-3 phenylmagnesium bromide 

Downstream Products

• 128092-75-1 (2-fluorophenyl)-(4-fluorophenyl)phenylchloromethane 
• 119006-77-8 flutrimazole 

Relevant academic research and scientific papers

Novel inhibitors of the gardos channel for the treatment of sickle cell disease

Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.

TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS

The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The com

GARDOS CHANNEL ANTAGONISTS

Novel inhibitors of potassium flux are disclosed. The inhibitors show surprising resistance to degradation in biological media and enhanced in vivo half-lives relative to non-fluorine substituted homologues. Methods for the use of these compounds include

Synthesis and antifungal activity of a series of difluorotritylimidazoles

1-[(2-Fluorophenyl)(4-fluorophenyl)phenylmethyl]-1H-imidazole (flutrimazole, UR-4056, CAS 119006-77-8) (15) was selected among a series of mono-, di- and trifluorotrityl-imidazole antifungal agents as the most potent fluorine containing analogue of clotrimazole.